The U.S. Food and Drug Administration (FDA) announced on March 24th that it will allow physicians to use convalescent plasma collected from recovered COVID-19 patients in patients with serious or immediately life-threatening COVID-19 infections. This will be through the process of single patient emergency Investigational New Drug Applications (eINDs) for Individual patients under 21 CFR 312.310. At the same time, the state of New York announced initiation of a clinical trial using blood plasma from patients who have recovered from COVID-19.